If ever a good compound was screwed up by a pharmaceutical company, this was it. First, letting tamiflu beat relenza in the US, then letting inavir die in fully funded but poorly designed and poorly executed US trials. Why? Because they sold the company cheap and brought in poor managers.
DS saw the potential in the compound so early. Biota were just stupid.
BTA Price at posting:
57.0¢ Sentiment: Hold Disclosure: Held
HotCopper & The Market Online will be live From the Floor at the Mining News Select Conference and we want to bring the voice of our online audience to the show with us.
